Samsung Biologics Acquires PolyPeptide Group for 2.7 Trillion Won
Samsung Biologics signed an acquisition agreement with PolyPeptide Group on the 20th for approximately 2.7 trillion won. The deal represents the largest merger and acquisition in Korea's pharmaceutical and biotechnology industry. Samsung Biologics plans to acquire 100% equity through majority
Samsung Biologics3.72%
LucasBennett·07-19 23:31
